Trending

atopic dermatitis

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

Pfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased

X

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

https://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/

Sanofi’s eczema drug gets EU approval to treat adolescents

Sanofi’s eczema drug gets EU approval to treat adolescents

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to

X

Sanofi’s eczema drug gets EU approval to treat adolescents

https://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/

Almirall takes option on Dermira’s eczema drug lebrikizumab

Almirall takes option on Dermira’s eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe,

X

Almirall takes option on Dermira’s eczema drug lebrikizumab

https://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/

Almirall signs atopic dermatitis R&D deal with Hitgen

Almirall signs atopic dermatitis R&D deal with Hitgen

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for

X

Almirall signs atopic dermatitis R&D deal with Hitgen

https://pharmaphorum.com/news/almirall-signs-atopic-dermatitis-rd-deal-with-hitgen/

NICE okays NHS funding for MS and eczema drugs

NICE okays NHS funding for MS and eczema drugs

The UK’s NICE endorsed regular NHS funding for big-selling drugs from Roche and Sanofi, changing its mind in

X

NICE okays NHS funding for MS and eczema drugs

https://pharmaphorum.com/news/nice-okays-nhs-funding-for-ms-and-eczema-drugs/

Sanofi’s blockbuster-tipped Dupixent set for European launches

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key

X

Sanofi’s blockbuster-tipped Dupixent set for European launches

https://pharmaphorum.com/news/sanofis-blockbuster-tipped-dupixent-set-european-launches/

Sanofi’s dermatitis drug dupilumab fast-tracked by FDA

Sanofi’s dermatitis drug dupilumab fast-tracked by FDA

Drug could earn $2.8 billion if approved in AD and asthma

X

Sanofi’s dermatitis drug dupilumab fast-tracked by FDA

https://pharmaphorum.com/news/sanofis-dermatitis-drug-dupilumab-fast-tracked-fda/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com